How has Allogene Therapeutics's operating lease liabilities changed year-over-year?

Allogene Therapeutics's operating lease liabilities decreased by 20.1% year-over-year, from -$1.83M to -$2.2M.

Allogene Therapeutics ALLO Operating lease liabilities

Operating lease liabilities at other companies

PrecigenPGEN

——

Immix Biopharma, Inc.IMMX

——

Vor BiopharmaVOR

——

Kyverna Therapeutics, Inc.KYTX

——

ImmunomeIMNM

——

Iovance Biotherapeutics, Inc.IOVA

——

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's operating lease liabilities?: Allogene Therapeutics (ALLO) reported operating lease liabilities of -$2.2M in Q1 2026.
How has Allogene Therapeutics's operating lease liabilities changed year-over-year?: Allogene Therapeutics's operating lease liabilities decreased by 20.1% year-over-year, from -$1.83M to -$2.2M.